Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot 'expeditiously'

The FDA has lifted the clinical hold on Selecta Bioscience’s gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial.